Viewing Study NCT04139434

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:39 AM
Ignite Modification Date: 2026-07-02 @ 11:32 AM
Study NCT ID: NCT04139434
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-04-24
First Post: 2019-10-18
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Sponsor: Newave Pharmaceutical Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None AML/MDS View
None CMML View
None Relapse View
None Refractory Acute Lymphoblastic Leukemia View
None Relapse Leukemia View
None Relapsed Adult AML View
Keywords:

Keywords

Keyword Brief Keyword Text View
None AML View
None MDS View
None CMML View
None relapse View
None refractory View
None LP-108 View